Vidac Pharma Announces Milestone Patent
Vidac Pharma Holdings Plc, an innovative clinical-stage biopharmaceutical company, has achieved a remarkable milestone in oncology. The United States Patent and Trademark Office (USPTO) has granted them a new patent, which protects their groundbreaking method of action for developing oncology and onco-dermatologic drug candidates.
Exploring the Mode of Action
This patent safeguards Vidac's novel chemical entities, which are designed to interfere with the hexokinase 2 isozyme's function in cancer metabolism. By detaching hexokinase 2 from the mitochondrial voltage-dependent anion channels (VDAC pores), Vidac aims to reverse the hyperglycolytic metabolism that cancer cells often exhibit. This approach has the potential to stop cancer cell growth, restore normal apoptosis, and address the immunosuppressive environment that typically aids tumor progression.
CEO’s Thoughts on the Patent
Following this news, Prof. Max Herzberg, CEO of Vidac Pharma, shared his enthusiasm: "This extremely wide-ranging patent is very welcome news for Vidac, given that it provides full protection of our efforts to bring an entirely new class of cancer treatments to market." He emphasized how Vidac's unique strategy of reversing the Warburg effect—a well-known metabolic characteristic of cancer cells—highlights the patent’s importance in the U.S. market.
Developing Product Candidates and Their Impact
Vidac Pharma is progressing with two primary product candidates: VDA-1275 and VDA-1102. These candidates work by blocking the interplay between hexokinase 2 and VDACs, which is crucial in cancer metabolism. Cancer cells often overproduce HK2, a factor that drives glucose metabolism and, in turn, fuels tumor growth. By obstructing VDAC channels, HK2 promotes anti-apoptotic signals, aiding cancer cell survival and fostering an acidic tumor microenvironment.
Clinical Studies and Outcomes
The clinical trials for Vidac’s initial metabolic checkpoint modulators have displayed promising results. These studies successfully halt cancer cell growth, restore immune response, and facilitate programmed cell death. Currently, VDA-1102 is in Phase 2b clinical trials, targeting advanced actinic keratosis, and is also being examined in Phase 2 trials for cutaneous T-cell lymphoma.
Potential for Combined Therapies
Besides its standalone effectiveness, VDA-1275 has shown significant positive outcomes when used alongside traditional cancer treatments, including sorafenib and cisplatin. Animal studies indicate that VDA-1275 may promote its own immune response, encouraging the formation of anti-tumor macrophages and memory T-cells, while inhibiting tumor-friendly macrophages and fostering a healthier immune environment.
About Vidac Pharma
Vidac Pharma is committed to discovering and developing first-in-class medications aimed at treating oncologic and onco-dermatologic conditions. The company aspires to offer innovative drug solutions that target metabolic checkpoints in cancer cells, promoting their programmed death while protecting healthy tissues. With its standout product candidate, VDA-1102, Vidac aims to meet significant unmet needs in treating advanced actinic keratosis and cutaneous T-cell lymphoma.
Contact Information
If you’d like more information, please reach out to Dr. Max Herzberg at Vidac Pharma Holdings Plc, situated at 20-22 Wenlock Road, London N1 7GU, United Kingdom. You can also contact them at +972-54-4257381 or +972-77-9300647.
Frequently Asked Questions
What is the significance of Vidac Pharma's new patent?
The patent grants Vidac Pharma extensive protection for its innovative approach to oncology treatment, particularly against the hyperglycolytic metabolism of cancer cells.
What are the primary product candidates developed by Vidac Pharma?
Vidac's primary product candidates are VDA-1275 and VDA-1102, which target hexokinase 2 and VDACs in cancer cells to halt growth and restore normal cell death processes.
How does VDA-1102 impact cancer treatment?
VDA-1102 shows promise in clinical studies for advanced actinic keratosis and cutaneous T-cell lymphoma, offering a potential new therapeutic option for patients.
What is the unique approach Vidac Pharma is taking?
Vidac Pharma focuses on reversing the Warburg effect in cancer cells, a unique approach that sets them apart in developing cancer therapies.
Who can be contacted for more information about Vidac Pharma?
Interested individuals can reach out to Dr. Max Herzberg at Vidac Pharma's London office for more information on the company's initiatives and drug candidates.
